Insulin glulisine--a comprehensive preclinical evaluation

Area of Science:

• Pharmacology and Toxicology
• Endocrinology
• Molecular Biology

Background:

• Insulin glulisine is a rapid-acting insulin analog used for diabetes management.
• Understanding its receptor binding, signaling, and mitogenic potential is crucial for safety assessment.
• Comparison with regular human insulin (RHI) and Asp(B10) provides valuable insights.

Purpose of the Study:

• To compare the in vivo and in vitro receptor binding, signaling, and mitogenic potential of insulin glulisine, RHI, and Asp(B10).
• To assess the safety profile of insulin glulisine relative to RHI through preclinical evaluation.

Main Methods:

• Receptor binding assays (insulin and IGF-1 receptors) using cell lines (293HEK, B10, K6 myoblasts).
• Insulin receptor-mediated signaling assessment (IRS-1/IRS-2 activation) in fibroblasts, myoblasts, and cardiomyocytes.
• DNA synthesis induction measured by [3H] thymidine incorporation in MCF10 cells.
• Long-term immunohistochemical examination of rat tissues.

Main Results:

• Insulin glulisine exhibited slightly lower insulin receptor binding affinity than RHI.
• Insulin glulisine showed lower IGF-1 receptor binding affinity compared to RHI and Asp(B10).
• Insulin glulisine and RHI displayed similar insulin receptor-mediated phosphorylation and IRS-2 activation, but glulisine had lower IRS-1 activation.
• Glulisine and RHI demonstrated comparable DNA synthesis stimulation and proliferative activity in long-term studies.

Conclusions:

• Structural modifications in insulin glulisine do not appear to be associated with safety issues compared to RHI in preclinical evaluations.
• Insulin glulisine's receptor interaction and signaling profile are comparable to RHI, supporting its safety in diabetes treatment.
• Further research may explore subtle differences in signaling pathways for a comprehensive understanding.